Table 1 Metronomic chemotherapy clinical trials in HNSCC patients

Patil et al. [16]

2015

phase II

110

celecoxib + methotrexate (57); cisplatinum (53)

OS 101 vs 66 days*; PFS 249 vs 152 days*

Pai et al. [17]

2013

retrospective

64

celecoxib + methotrexate (32); no MC (32)

2-year DFS 94.6 % vs 75.4 %*

Penel et al. [18]

2010

randomised

88

cyclophosphamide (44); megestrol acetate (44)

2-month PFS 20.5 % vs 9 %; median OS 195 vs 144 days